Quince Therapeutics
QNCX
43 hedge funds and large institutions have $1.44M invested in Quince Therapeutics in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 35 closing their positions.
7,560% more call options, than puts
Call options by funds: $766K | Put options by funds: $10K
0.11% less ownership
Funds ownership: 0.18% → 0.07% (-0.11%)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
31% less funds holding
Funds holding: 62 → 43 (-19)
51% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 35
98% less capital invested
Capital invested by funds: $67.5M → $1.44M (-$66M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$3.27M |
| 2 |
SC
Shay Capital
New York
|
+$1.78M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.74M |
| 4 |
Millennium Management
New York
|
+$1.32M |
| 5 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
+$133K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.95M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.54M |
| 3 |
AC
Almitas Capital
Santa Monica,
California
|
-$3.12M |
| 4 |
SCM
Superstring Capital Management
New York
|
-$2.88M |
| 5 |
SC
Stempoint Capital
New York
|
-$2.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EGM
76
Engineers Gate Manager
New York
| – | -$40.8K | -61 | Closed |
|
77
Wells Fargo
San Francisco,
California
| – | -$23.4K | -35 | Closed |
|
78
Citigroup
New York
| – | -$21.7K | -32 | Closed |
|
|
AF
79
Allworth Financial
Folsom,
California
| – | -$5.03K | -8 | Closed |
|
80
Fidelity Investments
Boston,
Massachusetts
| – | -$235 | – | – |
|
81
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$3.21K | +16 | New |
|
QNCX Hedge Fund Activity: Q1 2026 in Review
43 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q1 2026, worth a combined $1.44M — down 98% from $67.5M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of QNCX and 17 opened new positions — a net loss of 18 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Woodline Partners, adding an estimated $3.27M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $8.95M sold.
- 43 institutional investors held Quince Therapeutics (QNCX) as of Q1 2026, down from 62 in Q4 2025.
- Funds reported $1.44M of Quince Therapeutics stock for Q1 2026, down 98% quarter-over-quarter.
- 17 funds opened new Quince Therapeutics positions in Q1 2026 and 35 closed out, a net change of -18 holders.
- The largest Quince Therapeutics buyer in Q1 2026 was Woodline Partners, an estimated $3.27M added.
- The largest Quince Therapeutics seller in Q1 2026 was Nantahala Capital Management, an estimated $8.95M sold.
Based on aggregated 13F filings for Q1 2026.